Genetics

This blog post explores a major breakthrough in multiple sclerosis (MS) research, where scientists identified new biomarkers in both cerebrospinal fluid (CSF) and blood that could help diagnose MS earlier, track disease progression, and even monitor treatment effectiveness. Using a highly sensitive protein analysis method, the study found specific immune-related proteins—like IL-12B in CSF and oncostatin M (OSM) in plasma—that were elevated in people with MS. Some markers were linked to how long someone had the disease or how severe it was. Most importantly, two blood-based markers showed real promise, offering a less invasive way to help manage MS in the future.